Close
Achema middle east
swop processing & packaging

Acurian enters into agreement with pharma firm to handle patient data

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Artificial Intelligence in Pharmaceutical Process Control Trends

Artificial Intelligence in Pharmaceutical Process Control: What's Now and...

Using Digital Twins to Optimize Pharmaceutical Plant Performance

The pharmaceutical manufacturing sector stands at the forefront of...

Integration of Digital Biology with Pharmaceutical Manufacturing

Integration of Digital Biology with Pharmaceutical Manufacturing Workflows The pharmaceutical...

Acurian, a provider of clinical trial patient recruitment and retention solutions, has entered into an agreement with a pharma firm to handle patient recruitment and retention data.The agreement allows Acurian to use encryption and security standards to manage sensitive patient data handled within its Oracle- and cloud-based computing platforms known as Acurian Recruitment Manager and Acurian Retention Manager. The agreement is based primarily on Oracle’s Advanced Security Option (ASO) software to further ensure that data storage and transfer capabilities required in a global patient recruitment and retention platform are fully secure.The data stored aids them to submit the clinical trial patient information for regulatory submissions.

Acurian Operations senior vice president Roger Smith said they have invested tens of millions of dollars in infrastructure, personnel, procedures, and systems so that they can collect, store, and transmit data that sponsors and regulators classify as highly-sensitive.

“It’s clear that any supplier unable to meet these expectations will be unable to do business in accordance with the policies and procedures of large pharma especially, but with any company that expects to adhere to Good Clinical Practices,” Smith said.

Latest stories

Related stories

Artificial Intelligence in Pharmaceutical Process Control Trends

Artificial Intelligence in Pharmaceutical Process Control: What's Now and...

Using Digital Twins to Optimize Pharmaceutical Plant Performance

The pharmaceutical manufacturing sector stands at the forefront of...

Integration of Digital Biology with Pharmaceutical Manufacturing

Integration of Digital Biology with Pharmaceutical Manufacturing Workflows The pharmaceutical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »